Baclofen Versus Gabapentin in Preventing Postoperative Pain After Laparoscopic Sleeve Gastrectomy

Sponsor
Tanta University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05921604
Collaborator
(none)
100
1
2
14.1
7.1

Study Details

Study Description

Brief Summary

The aim of this study is to compare the possible efficacy of baclofen and gabapentin on postoperative pain in patient with morbid obesity who will undergo laparoscopic sleeve gastrectomy.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Prevention
Official Title:
Baclofen Versus Gabapentin in Preventing Postoperative Pain After Laparoscopic Sleeve
Anticipated Study Start Date :
Jun 30, 2023
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1 (baclofen)

which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.

Drug: Baclofen 10mg
which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.

Experimental: Group 2 (gabapentin)

which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.

Drug: Gabapentin
which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.

Outcome Measures

Primary Outcome Measures

  1. visual analog scale (VAS) score [The first 48 hours after surgery.]

    During the first 48-h postoperative study period, patients were asked to rate their intensity of pain using visual analog scale (VAS) scores. the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Based on the distribution of pain VAS scores in post-surgical patients (knee replacement, hysterectomy, or laparoscopic myomectomy who described their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm)

Secondary Outcome Measures

  1. sedation score [The first 48 hours after surgery.]

    Postoperative sedation scores will be evaluated using the following scale: 0 = awake, 1 = mild sedation, 2 = sleepy but arousable, and 3 = very sleepy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
    • Age between 18-60 years old.
  • Both male and female patients will be included.

  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the presence of comorbidity such as hypertension, arthritis, and diabetes.

  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without comorbidity.

  • Patients fit for anesthesia and surgery.

Exclusion Criteria:
  • Patients with BMI >55 kg/m2.

  • Patients with previous procedures for the treatment of obesity.

  • Pregnant females and lactating women.

  • Patients with psychological or psychiatric disease

  • Administration of antiemetic medication or systemic corticosteroids within 24 hours before surgery

  • Patients who experienced vomiting within 24 hours before surgery.

  • Patients with history of alcohol or drug abuse.

  • Patients with hypersensitivity or contraindications to any of the drugs used in this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, Egypt Tanta Gharbiya Egypt 31111

Sponsors and Collaborators

  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aya Gamal Moussa, Assistant Lecturer at Clinical Pharmacy department , Faculty of Pharmacy -Tanta University, Tanta University
ClinicalTrials.gov Identifier:
NCT05921604
Other Study ID Numbers:
  • 35648
First Posted:
Jun 27, 2023
Last Update Posted:
Jun 27, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2023